Evidence map›Paper›PMID 38988891›Full record

ReviewFrontiers in genome editing2024

Advancing crop disease resistance through genome editing: a promising approach for enhancing agricultural production.

Subaya Manzoor, Sajad Un Nabi, Tariq Rasool Rather, Gousia Gani, Zahoor Ahmad Mir, Ab Waheed Wani, Sajad Ali, Anshika Tyagi, Nazia Manzar

Abstract readReview
In one paragraph

Review in Frontiers in genome editing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. CRISPR/Cas Genome Editing and Its Applications in Cereal Crop Improvement.Plant-environment interactions (Hoboken, N.J.) · 2026
    Review
  4. Developing improved inoculants through genome editing of diazotrophic bacteria for cereals: Is this the right time for Brazil?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  5. Genome editing of susceptibility geneFrontiers in plant science · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Subaya ManzoorDivision of Plant Pathology, FOA-SKUAST-K, Wadura, Srinagar, India.
Sajad Un NabiICAR-Central Institute of Temperate Horticulture, Srinagar, India.
Tariq Rasool RatherDivision of Plant Pathology, SKUAST-K Shalimar, Srinagar, India.
Gousia GaniDivision of Basic Science and Humanities, FOA-SKUAST-K, Wadura, Srinagar, India.
Zahoor Ahmad MirDepartment of Plant Science and Agriculture, University of Manitoba, Winnipeg, MB, Canada.
Ab Waheed WaniDepartment of Horticulture, LPU, Jalander, Punjab, India.
Sajad AliDepartment of Biotechnology, Yeungnam University, Gyeongsan, Republic of Korea.
Anshika TyagiDepartment of Biotechnology, Yeungnam University, Gyeongsan, Republic of Korea.
Nazia ManzarPlant Pathology Lab, ICAR-National Bureau of Agriculturally Important Microorganism, Mau, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modern agriculture has encountered several challenges in achieving constant yield stability especially due to disease outbreaks and lack of long-term disease-resistant crop cultivars. In the past, disease outbreaks in economically important crops had a major impact on food security and the economy. On the other hand climate-driven emergence of new pathovars or changes in their host specificity further poses a serious threat to sustainable agriculture. At present, chemical-based control strategies are frequently used to control microbial pathogens and pests, but they have detrimental impact on the environment and also resulted in the development of resistant phyto-pathogens. As a replacement, cultivating engineered disease-resistant crops can help to minimize the negative impact of regular pesticides on agriculture and the environment. Although traditional breeding and genetic engineering have been instrumental in crop disease improvement but they have certain limitations such as labour intensity, time consumption, and low efficiency. In this regard, genome editing has emerged as one of the potential tools for improving disease resistance in crops by targeting multiple traits with more accuracy and efficiency. For instance, genome editing techniques, such as CRISPR/Cas9, CRISPR/Cas13, base editing, TALENs, ZFNs, and meganucleases, have proved successful in improving disease resistance in crops through targeted mutagenesis, gene knockouts, knockdowns, modifications, and activation of target genes. CRISPR/Cas9 is unique among these techniques because of its remarkable efficacy, low risk of off-target repercussions, and ease of use. Some primary targets for developing CRISPR-mediated disease-resistant crops are host-susceptibility genes (the S gene method), resistance genes (R genes) and pathogen genetic material that prevents their development, broad-spectrum disease resistance. The use of genome editing methods has the potential to notably ameliorate crop disease resistance and transform agricultural practices in the future. This review highlights the impact of phyto-pathogens on agricultural productivity. Next, we discussed the tools for improving disease resistance while focusing on genome editing. We provided an update on the accomplishments of genome editing, and its potential to improve crop disease resistance against bacterial, fungal and viral pathogens in different crop systems. Finally, we highlighted the future challenges of genome editing in different crop systems for enhancing disease resistance.

Indexed as

disease resistancegenome editing crisprmeganucleasespathogensTALENZFN

Identifiers

PMID38988891
PMCPMC11234172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.